TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG BID VS REMAINING ON 10 MG BID IN PATIENTS WITH UC WHO WERE IN STABLE REMISSION ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Severine Vermeire  ¹     Chinyu Su  ²     Nervin Lawendy  ²     Taku Kobayashi  ³     William Sandborn  ⁴     David T. Rubin  ⁵     Irene Modesto  ⁶     Sean Gardiner  ⁶     nicole kulisek  ⁷     Haiying Zhang  ⁷     Wenjin Wang  ⁷     Julian Panés  ^8    
1 University Hospitals Leuven, Leuven, Belgium
² Pfizer Inc, Collegeville, PA, United States
³ Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
⁴ University of California San Diego, La Jolla, United States
⁵ University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States
⁶ Pfizer Inc, New York, United States
⁷ Pfizer Inc, Collegeville, United States
⁸ Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

Topic
IBD, Immunology, Paediatrics

Session
IBD: Mixed trials

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)